DK0917879T3 - Forbedret fremgangsmåde til stabilisering af proteiner - Google Patents

Forbedret fremgangsmåde til stabilisering af proteiner

Info

Publication number
DK0917879T3
DK0917879T3 DK98121684T DK98121684T DK0917879T3 DK 0917879 T3 DK0917879 T3 DK 0917879T3 DK 98121684 T DK98121684 T DK 98121684T DK 98121684 T DK98121684 T DK 98121684T DK 0917879 T3 DK0917879 T3 DK 0917879T3
Authority
DK
Denmark
Prior art keywords
stabilization method
protein stabilization
improved protein
improved
stabilization
Prior art date
Application number
DK98121684T
Other languages
Danish (da)
English (en)
Inventor
Klaus Hellerbrand
Apollon Papadimitriou
Gerhard Winter
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26145913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0917879(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0917879T3 publication Critical patent/DK0917879T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/963Methods of stopping an enzyme reaction or stabilizing the test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK98121684T 1997-11-22 1998-11-13 Forbedret fremgangsmåde til stabilisering af proteiner DK0917879T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120528 1997-11-22
EP98102846 1998-02-19

Publications (1)

Publication Number Publication Date
DK0917879T3 true DK0917879T3 (da) 2002-11-04

Family

ID=26145913

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98121684T DK0917879T3 (da) 1997-11-22 1998-11-13 Forbedret fremgangsmåde til stabilisering af proteiner

Country Status (16)

Country Link
US (1) US6238664B1 (fr)
EP (1) EP0917879B1 (fr)
JP (1) JP3105494B2 (fr)
KR (1) KR100315908B1 (fr)
CN (1) CN1220270A (fr)
AR (2) AR018020A1 (fr)
AT (1) ATE220558T1 (fr)
AU (1) AU714264B2 (fr)
BR (1) BRPI9805021B8 (fr)
CA (1) CA2254145C (fr)
DE (1) DE59804785D1 (fr)
DK (1) DK0917879T3 (fr)
ES (1) ES2179414T3 (fr)
PT (1) PT917879E (fr)
TR (1) TR199802394A2 (fr)
ZA (1) ZA9810650B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030175827A1 (en) * 2002-03-14 2003-09-18 Stillman Brett A. Stable thin film dried protein composition or device and related methods
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
WO2007016562A2 (fr) * 2005-07-29 2007-02-08 Amgen Inc. Formulations inhibant l'agregation de proteines
EP2076287A2 (fr) * 2006-10-12 2009-07-08 Wyeth Procédés et compositions ayant une opalescence réduite
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
BR112017006533A2 (pt) * 2014-09-29 2017-12-19 Cook General Biotechnology Llc usos de trealose em suspensões celulares
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
CN111781345A (zh) * 2020-06-30 2020-10-16 上海透景生命科技股份有限公司 化学发光标记物标记抗原稳定剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
CA1329760C (fr) 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
GB8726136D0 (en) * 1987-11-07 1987-12-09 Wellcome Found Therapeutic nucleosides
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE3863908D1 (de) 1987-11-27 1991-08-29 Akzo Nv Stabilisierung von antikoerpern.
GB8920534D0 (en) * 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
US5164296A (en) * 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
RU2109290C1 (ru) * 1996-04-09 1998-04-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Стабилизирующий состав для получения лиофилизированных препаратов на основе конъюгата антииммуноглобулина g и пероксидазы хрена
EP0852951A1 (fr) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux

Also Published As

Publication number Publication date
BRPI9805021A (pt) 2000-03-21
EP0917879A2 (fr) 1999-05-26
EP0917879A3 (fr) 1999-06-09
ES2179414T3 (es) 2003-01-16
ATE220558T1 (de) 2002-08-15
CA2254145C (fr) 2002-10-08
TR199802394A3 (tr) 1999-06-21
KR19990045460A (ko) 1999-06-25
BRPI9805021B8 (pt) 2021-07-06
DE59804785D1 (de) 2002-08-22
BRPI9805021B1 (pt) 2011-05-31
CN1220270A (zh) 1999-06-23
AU714264B2 (en) 1999-12-23
EP0917879B1 (fr) 2002-07-17
US6238664B1 (en) 2001-05-29
PT917879E (pt) 2002-12-31
JP3105494B2 (ja) 2000-10-30
JPH11240895A (ja) 1999-09-07
ZA9810650B (en) 1999-05-24
TR199802394A2 (xx) 1999-06-21
KR100315908B1 (ko) 2002-04-24
AR034226A2 (es) 2004-02-04
AR018020A1 (es) 2001-10-31
AU9406098A (en) 1999-06-10
CA2254145A1 (fr) 1999-05-22

Similar Documents

Publication Publication Date Title
DK0917879T3 (da) Forbedret fremgangsmåde til stabilisering af proteiner
DK1011309T3 (da) Fremgangsmåde til tilvejebringelse af forøget fotosyntese
FI971620A7 (fi) Autentikointimenetelmä
DK0875252T3 (da) Formuleringer af aktiveret protein C
IS8368A (is) Ný aðferð
NO982097L (no) Peptider
NO982098L (no) Peptider
DE69808188D1 (de) Bilddekodierungsverfahren
DE69830295D1 (de) Steuerungsverfahren
NO2010022I1 (no) Denosumab
DE69839978D1 (de) Fluorpolymerstabilisierung
FI972024L (fi) Kanavanvaihtomenetelmä
ATE260674T1 (de) Stabilisierte proteinzusammensetzung
DE69815975D1 (de) Steuerungsverfahren
IS5106A (is) Ný aðferð
DE59809684D1 (de) Stabilisator
DE69837784D1 (de) Verbessertes fünf-fehler-korrektursystem
IS5043A (is) Aðferð til að mynda stafræna undirskrift
DK0987356T3 (da) Fremgangsmåde til trækning
DE69816734D1 (de) Steuerungsverfahren
DE69925271D1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
DK1524268T3 (da) Forbindelser og fremgangsmåde til fremstilling af substituerede 4-phenyl-4-cyanocyclohexansyrer
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
DE69837899D1 (de) Elektrophoreseapparatur